CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH (CHARTER) EXTENSION

CNS HIV 抗逆转录病毒治疗效果研究（章程）扩展

• 批准号: 8737536
• 负责人: IGOR GRANT
• 金额: $ 102.72万
• 依托单位: CALIFORNIA UNIV SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-16 至 2015-09-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8737536
• 关键词: AIDS neuropathy; Address; Anti-Retroviral Agents; Biological Preservation; Blood; Brain; California; Cells; Cognition; DNA; Disease; Evolution; Failure; Funding; Goals; HIV; Highly Active Antiretroviral Therapy; Image; Impaired cognition; Individual; Laboratories; Light; MRI Scans; Magnetic Resonance Imaging; Medical; Morbidity - disease rate; Nerve Fibers; Nervous System Trauma; Nervous system structure; Neurocognitive; Neurologic; Neuropathy; Participant; Performance; Peripheral Nervous System Diseases; Plasma; Population; Procedures; Protocols documentation; RNA; Research; Research Personnel; Research Project Grants; Role; Schwann Cells; Site; Texas; Universities; Washington; antiretroviral therapy; base; cohort; density; follow-up; medical schools; mortality; neuropsychological; performance site; quality assurance; virus genetics; white matter

The CNS HIV Antiretroviral Therapy Effects Research (CHARTER) was funded in 2002 with the aim of exploring the changing presentation of HIV neurological complications in the context of highly active antiretroviral therapy (HAART). The six performance sites of CHARTER (Johns Hopkins University, Mt. Sinai Medical School, University of California at San Diego, University of Texas Medical Branch at Galveston, University of Washington, Washington University at St. Louis), representing a diverse participant pool as well as investigators with expertise in various aspects of NeuroAIDS, were able to standardize neuromedical, neuropsychological, psychiatric, neuropathy, and imaging protocols along with on-going quality assurance procedures. Two key conclusions to emerge from the CHARTER project are that HIV-Associated Neurocognitive Disorders (HAND) and peripheral neuropathy remain highly prevalent despite effective HIV treatments that have significantly reduced mortality and non-neurologic morbidities. In CHARTER Extension, 180 participants (30 per site) from the original CHARTER longitudinal cohort have been selected for further study based on the goal of shedding light on CSF virologic failure, low-level HIV replication, worsening cognition and abnormal white matter, as well on-going peripheral neuropathy. These individuals will be assessed annually using well-established neuropsychological, neuromedical, laboratory, and neuropathy assessments. A subset of participants will complete annual brain MRI scans.

CNS HIV 抗逆转录病毒治疗效果研究 (CHARTER) 于 2002 年资助，旨在探索高效抗逆转录病毒治疗 (HAART) 背景下 HIV 神经并发症的变化。 CHARTER 的六个演出场地（约翰·霍普金斯大学、西奈山医学院、加州大学圣地亚哥分校、德克萨斯大学加尔维斯顿分校医学部、华盛顿大学、华盛顿大学圣路易斯分校）代表了多元化的参与者群体：以及在 NeuroAIDS 各个方面具有专业知识的研究人员，能够标准化神经医学、神经心理学、精神病学、神经病和成像协议以及持续的质量保证程序。 CHARTER 项目得出的两个关键结论是，尽管有效的 HIV 治疗显着降低了死亡率和非神经系统发病率，但 HIV 相关神经认知障碍 (HAND) 和周围神经病变仍然非常普遍。在 CHARTER Extension 中，从原始 CHARTER 纵向队列中选择了 180 名参与者（每个中心 30 名）进行进一步研究，目标是揭示 CSF 病毒学失败、低水平 HIV 复制、认知恶化和白质异常等问题持续的周围神经病变。这些人每年都会使用完善的神经心理学、神经医学、实验室和神经病评估进行评估。一部分参与者将完成年度脑部核磁共振扫描。